\BOOKMARK [-1][-]{chapter*.1}{Abstract}{}% 1
\BOOKMARK [-1][-]{chapter*.2}{Zusammenfassung}{}% 2
\BOOKMARK [-1][-]{chapter*.3}{Acknowledgements}{}% 3
\BOOKMARK [-1][-]{section*.4}{Nomenclature}{}% 4
\BOOKMARK [-1][-]{part.1}{Introduction}{}% 5
\BOOKMARK [0][-]{chapter.1}{Discovery and brief history}{part.1}% 6
\BOOKMARK [0][-]{chapter.2}{Taxonomy}{part.1}% 7
\BOOKMARK [1][-]{section.2.1}{The Parvovirinae subfamily}{chapter.2}% 8
\BOOKMARK [2][-]{subsection.2.1.1}{Amdoparvovirus}{section.2.1}% 9
\BOOKMARK [2][-]{subsection.2.1.2}{Aveparvovirus}{section.2.1}% 10
\BOOKMARK [2][-]{subsection.2.1.3}{Bocaparvovirus}{section.2.1}% 11
\BOOKMARK [2][-]{subsection.2.1.4}{Copiparvovirus}{section.2.1}% 12
\BOOKMARK [2][-]{subsection.2.1.5}{Dependoparvovirus}{section.2.1}% 13
\BOOKMARK [2][-]{subsection.2.1.6}{Erythroparvovirus}{section.2.1}% 14
\BOOKMARK [2][-]{subsection.2.1.7}{Protoparvovirus}{section.2.1}% 15
\BOOKMARK [2][-]{subsection.2.1.8}{Tetraparvovirus}{section.2.1}% 16
\BOOKMARK [0][-]{chapter.3}{Morphology}{part.1}% 17
\BOOKMARK [0][-]{chapter.4}{The rugged virion}{part.1}% 18
\BOOKMARK [1][-]{section.4.1}{Physicochemical Properties}{chapter.4}% 19
\BOOKMARK [1][-]{section.4.2}{Atomic Model}{chapter.4}% 20
\BOOKMARK [1][-]{section.4.3}{Structural Proteins}{chapter.4}% 21
\BOOKMARK [1][-]{section.4.4}{Functional Domains}{chapter.4}% 22
\BOOKMARK [2][-]{subsection.4.4.1}{The Phospholipase A2 \(PLA2\) Motif}{section.4.4}% 23
\BOOKMARK [2][-]{subsection.4.4.2}{The Nuclear Localization Signal \(NLS\)}{section.4.4}% 24
\BOOKMARK [2][-]{subsection.4.4.3}{The Nuclear Localization Motif \(NLM\)}{section.4.4}% 25
\BOOKMARK [0][-]{chapter.5}{Genome Architecture}{part.1}% 26
\BOOKMARK [1][-]{section.5.1}{The MVM Left- and Right-End Telomeres}{chapter.5}% 27
\BOOKMARK [2][-]{subsection.5.1.1}{Terminal Resolution versus Asymmetric Junction Resolution}{section.5.1}% 28
\BOOKMARK [1][-]{section.5.2}{Genetic variability}{chapter.5}% 29
\BOOKMARK [0][-]{chapter.6}{Host Range and Specificity}{part.1}% 30
\BOOKMARK [1][-]{section.6.1}{Tissue Tropism Determinants}{chapter.6}% 31
\BOOKMARK [1][-]{section.6.2}{Pathogenicity Determinants}{chapter.6}% 32
\BOOKMARK [1][-]{section.6.3}{Comparison of Tissue Tropism and Pathogenicity Determinants among Parvoviurses}{chapter.6}% 33
\BOOKMARK [0][-]{chapter.7}{The Parvovirus Life Cycle}{part.1}% 34
\BOOKMARK [1][-]{section.7.1}{Receptor Binding}{chapter.7}% 35
\BOOKMARK [1][-]{section.7.2}{Receptor-mediated Endocytosis}{chapter.7}% 36
\BOOKMARK [1][-]{section.7.3}{Endosomal Trafficking and Capsid Rearrangements}{chapter.7}% 37
\BOOKMARK [1][-]{section.7.4}{Endosomal Escape}{chapter.7}% 38
\BOOKMARK [1][-]{section.7.5}{Cytosolic Trafficking and Interactions with the Proteasome}{chapter.7}% 39
\BOOKMARK [1][-]{section.7.6}{Nuclear Targeting}{chapter.7}% 40
\BOOKMARK [2][-]{subsection.7.6.1}{Nuclear Translocation of the Incoming Virion}{section.7.6}% 41
\BOOKMARK [2][-]{subsection.7.6.2}{Nuclear Translocation of the Structural Proteins}{section.7.6}% 42
\BOOKMARK [1][-]{section.7.7}{Non-structural \(NS\) proteins}{chapter.7}% 43
\BOOKMARK [2][-]{subsection.7.7.1}{Non-structural portein 1 \(NS1\)}{section.7.7}% 44
\BOOKMARK [2][-]{subsection.7.7.2}{Non-structural protein 2 \(NS2\)}{section.7.7}% 45
\BOOKMARK [2][-]{subsection.7.7.3}{Small alternatively translated \(SAT\) protein}{section.7.7}% 46
\BOOKMARK [1][-]{section.7.8}{Replication}{chapter.7}% 47
\BOOKMARK [1][-]{section.7.9}{Transcription and RNA processing}{chapter.7}% 48
\BOOKMARK [1][-]{section.7.10}{Assembly}{chapter.7}% 49
\BOOKMARK [1][-]{section.7.11}{DNA Packaging}{chapter.7}% 50
\BOOKMARK [1][-]{section.7.12}{Nuclear Export}{chapter.7}% 51
\BOOKMARK [1][-]{section.7.13}{Egress}{chapter.7}% 52
\BOOKMARK [0][-]{chapter.8}{Aim of the thesis and experimental strategy}{part.1}% 53
\BOOKMARK [1][-]{section.8.1}{Goals}{chapter.8}% 54
\BOOKMARK [1][-]{section.8.2}{Experimental strategy}{chapter.8}% 55
\BOOKMARK [-1][-]{part.2}{Methods}{}% 56
\BOOKMARK [0][-]{chapter.9}{Methods}{part.2}% 57
\BOOKMARK [1][-]{section.9.1}{Cell Cultures}{chapter.9}% 58
\BOOKMARK [2][-]{subsection.9.1.1}{Freezing and thawing of cells}{section.9.1}% 59
\BOOKMARK [1][-]{section.9.2}{Virus Stocks}{chapter.9}% 60
\BOOKMARK [2][-]{subsection.9.2.1}{Separation of empty and full capsids}{section.9.2}% 61
\BOOKMARK [1][-]{section.9.3}{Freezing bacteria stocks in glycerol}{chapter.9}% 62
\BOOKMARK [1][-]{section.9.4}{Fast protein liquid chromatography \(FPLC\)}{chapter.9}% 63
\BOOKMARK [2][-]{subsection.9.4.1}{Anion-exchange chromatography \(AEX\)}{section.9.4}% 64
\BOOKMARK [1][-]{section.9.5}{Quantitative PCR \(qPCR\)}{chapter.9}% 65
\BOOKMARK [1][-]{section.9.6}{Virus infection}{chapter.9}% 66
\BOOKMARK [1][-]{section.9.7}{Transfection}{chapter.9}% 67
\BOOKMARK [1][-]{section.9.8}{Cell fractionation}{chapter.9}% 68
\BOOKMARK [2][-]{subsection.9.8.1}{Nuclei isolation}{section.9.8}% 69
\BOOKMARK [2][-]{subsection.9.8.2}{Extraction of the cytoplasm}{section.9.8}% 70
\BOOKMARK [1][-]{section.9.9}{Immunoprecipitation \(IP\)}{chapter.9}% 71
\BOOKMARK [1][-]{section.9.10}{Dot Blot}{chapter.9}% 72
\BOOKMARK [1][-]{section.9.11}{SDS-PAGE and Western blotting \(WB\)}{chapter.9}% 73
\BOOKMARK [1][-]{section.9.12}{Enzymatic reactions}{chapter.9}% 74
\BOOKMARK [-1][-]{part.3}{Publication}{}% 75
\BOOKMARK [0][-]{chapter.1}{Wolfisberg et al., Journal of Virological Methods, 2013}{part.3}% 76
\BOOKMARK [1][-]{section*.21}{Impaired genome encapsidation restricts the in vitro propagation of human parvovirus B19.}{chapter.1}% 77
\BOOKMARK [-1][-]{part.4}{Results}{}% 78
\BOOKMARK [0][-]{chapter.2}{Supplementary Data}{part.4}% 79
\BOOKMARK [1][-]{section.2.1}{The phosphoserine-rich N-VP2 of MVM facilitates nuclear targeting and contributes to cytotoxicity.}{chapter.2}% 80
\BOOKMARK [1][-]{section.2.2}{Isolation and characterization of empty capsids \(EC\)}{chapter.2}% 81
\BOOKMARK [1][-]{section.2.3}{Full capsids \(FC\) bind preferentially to murine fibroblasts}{chapter.2}% 82
\BOOKMARK [1][-]{section.2.4}{N-VP2 is not sufficient to provide an advantage in binding for FC}{chapter.2}% 83
\BOOKMARK [1][-]{section.2.5}{Anion-exchange chromatography \(AEX\) can be applied on other parvoviruses}{chapter.2}% 84
\BOOKMARK [-1][-]{part.5}{Discussion}{}% 85
\BOOKMARK [0][-]{chapter.3}{Conclusion}{part.5}% 86
\BOOKMARK [-1][-]{part.6}{Appendix}{}% 87
\BOOKMARK [0][-]{chapter.9}{Materials}{part.6}% 88
\BOOKMARK [1][-]{section.9.1}{Infectious clone of MVMp \(pIC\137MVMp\)}{chapter.9}% 89
\BOOKMARK [2][-]{subsection.9.1.1}{Plasmid map of pIC\137MVMp}{section.9.1}% 90
\BOOKMARK [2][-]{subsection.9.1.2}{Complete sequence of pIC\137MVMp}{section.9.1}% 91
\BOOKMARK [1][-]{section.9.2}{Chemicals and compounds}{chapter.9}% 92
\BOOKMARK [1][-]{section.9.3}{Buffers}{chapter.9}% 93
\BOOKMARK [2][-]{subsection.9.3.1}{General buffers}{section.9.3}% 94
\BOOKMARK [2][-]{subsection.9.3.2}{Chromatography buffers}{section.9.3}% 95
\BOOKMARK [2][-]{subsection.9.3.3}{Agarose gel electrophoresis}{section.9.3}% 96
\BOOKMARK [2][-]{subsection.9.3.4}{Western blot}{section.9.3}% 97
\BOOKMARK [1][-]{section.9.4}{Kits}{chapter.9}% 98
\BOOKMARK [1][-]{section.9.5}{Enzymes}{chapter.9}% 99
\BOOKMARK [1][-]{section.9.6}{Antibodies}{chapter.9}% 100
\BOOKMARK [2][-]{subsection.9.6.1}{Primary antibodies}{section.9.6}% 101
\BOOKMARK [2][-]{subsection.9.6.2}{Secondary antibodies}{section.9.6}% 102
\BOOKMARK [1][-]{section.9.7}{Media}{chapter.9}% 103
\BOOKMARK [-1][-]{section*.41}{Bibliography}{}% 104
\BOOKMARK [-1][-]{section*.42}{Declaration}{}% 105
